STAT+: Amgen’s $27.8 billion Horizon merger is latest industry bet on pricey rare disease drugs
STAT
DECEMBER 12, 2022
Amgen said Monday it would purchase Horizon Pharmaceuticals for $27.8 billion, marking the latest bet by a large pharmaceutical company on the lucrative market for treating a rare disease. However, Amgen is now a much larger company, with annual revenues of $26 billion and a market capitalization of almost $150 billion.
Let's personalize your content